Sorafenib

“combinations such as atezolizumab plus bevacizumab, tremelimumab plus durvalumab, or monotherapies such as lenvatinib, sorafenib, tislelizumab, durvalumab, or pembrolizumab, at...” NCT06841172 ↗

“The first-line targeted-immunotherapy regimens consisted of tislelizumab combined with one of the first-line evidence-based tyrosine kinase inhibitors (TKIs), including...” NCT07463248 ↗

“Standardized FDG-PET/CT was performed at baseline and after the first cycle of combined sorafenib (600mg/day for 21 days, then 800mg/day) and capecitabine (1700 mg/m²/day...” PMID 26421426 ↗ Sep 2015

“TKI (Sorafenib 400mg, bid, po or Lenvatinib 8mg, qd, po if bodyweight less than 60 kg,12mg, qd, po if bodyweight more than 60kg or Donafenib：200mg, bid, po) +...” NCT06041490 ↗

“Treatment period: Therapeutic agents were selected according to clinical routine, including but not limited to Sorafenib, Lenvatinib, Donafenib, Regorafenib, Apatinib and Cabozantinib.” NCT05673824 ↗

“Sorafenib is a drug that has been approved to treat kidney and liver cancer (hepatocellular carcinoma, or HCC) and has been shown to prolong survival in patients with HCC.” NCT01306058 ↗

“The objective of the study is to compare the pharmacokinetics (PK) of sorafenib after the administration of 100 mg DPH001 vs. after the administration of 200 mg Nexavar®.” NCT06797427 ↗

“Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2).” PMID 28950297 ↗ Nov 2017

“Patients diagnosed as hepatocellular carcinoma will be randomly assigned for treatment with Sorafenib. Tab. Sorafenib will be given at doses of 200 mg 12 hourly.” NCT05391867 ↗

“High-risk group：Chemotherapy with the C-CD+ICE+ sorafenib regimen for 3 to 5 courses was followed by elective surgery, with a total of 6 to 7 courses” NCT07300449 ↗

Show 650 more sources

“This report describes the U.S. Food and Drug Administration (FDA) review and approval of sorafenib (Nexavar, BAY43-9006), a new small-molecule, oral, multi-kinase inhibitor for...” PMID 17189398 ↗ Dec 2006

“Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose...” NCT00494299 ↗

“This is an investigational study. Sorafenib (BAY 43-9006) has been approved by the FDA for treatment of advanced renal cell cancer; however, it's use in this research study is...” NCT00411671 ↗

“A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias” NCT01445080 ↗

“Sorafenib (Nexavar, BAY43-9006) 200 mg tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)” NCT00108953 ↗

“Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma” NCT00418496 ↗

“Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor with effects on tumor proliferation and tumor angiogenesis.” NCT01510756 ↗

“A Phase I Study of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib; Tarceva) in Advanced Solid Tumors” NCT00126620 ↗

“II. To assess objective response rate of sorafenib (BAY 43-9006) in sporadic metastatic medullary thyroid carcinoma.” NCT00390325 ↗

“Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature.” NCT00866320 ↗

Show 71 more sources

“The purpose of this study is to test the combination of radiation treatment and an anti-angiogenic drug called sorafenib (or BAY 43-9006 or Nexavar) to determine the effects of...” NCT00610246 ↗

“This report describes the U.S. Food and Drug Administration (FDA) review and approval of sorafenib (Nexavar, BAY43-9006), a new small-molecule, oral, multi-kinase inhibitor for...” PMID 17189398 ↗ Dec 2006

“Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose...” NCT00494299 ↗

“Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food...” NCT01170104 ↗

“Subjects are invited to participate in this study that will examine the use of three drugs called Sorafenib (Nexavar), Vorinostat (Zolinza) and Bortezomib (Velcade) for...” NCT01534260 ↗

“The purpose of this study is to evaluate the combination of Revlimid® (lenalidomide) and Nexavar® (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured...” NCT01348503 ↗

“Randomized Phase II Trial Assessing the Combination of Nexavar® (Sorafenib), and Gemcitabine/Oxaliplatin in Patients Treated for Advanced (Unresectable/Metastatic)...” NCT00941967 ↗

“To evaluate the efficacy and safety of a combined treatment with Sorafenib (Nexavar®) and pegylated interferon-α-2b (PegIntron®) in patients with malignant melanoma in stage IV.” NCT00623402 ↗

“A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma” NCT04000737 ↗

“Sorafenib (Nexavar, BAY43-9006) 200 mg tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)” NCT00108953 ↗

Show 69 more sources

“nexavar - sorafenib” NCT00808145 ↗

“Nexavar (Sorafenib)” NCT00825734 ↗

“Nexavar (sorafenib)” NCT01425216 ↗

“Nexavar (Sorafenib)” NCT00875745 ↗

“A phase 3, multinational, randomized, non-inferiority trial (REFLECT) compared the efficacy and safety of lenvatinib (LEN) and sorafenib (SOR) in patients with unresectable...” PMID 31720835 ↗ Nov 2019

“Everolimus (EVE) and sorafenib (SOR) combination was associated with synergistic activity in preclinical models.” PMID 36840749 ↗ Feb 2023

“Sorafenib (SOR)” NCT03037437 ↗

“sorafenib = nexavar” NCT01320111 ↗

“sorafenib (Nexavar)” NCT00844883 ↗

“sorafenib - Nexavar” NCT00780169 ↗

“Sorafenib (Nexavar)” NCT01640665 ↗

“To compare the progression-free survival (PFS) rates of patients with desmoid tumors (DT)/deep fibromatosis (DF) who receive either sorafenib (sorafenib tosylate) or placebo...” NCT02066181 ↗

“To determine the objective response rate to sorafenib tosylate (sorafenib) in children with relapsed or refractory rhabdomyosarcoma, Wilms tumor, hepatocellular carcinoma...” NCT01502410 ↗

“To define a safe dose of sorafenib (sorafenib tosylate) to combine with riluzole in the treatment of patients with all types of solid tumors refractory to standard therapy or...” NCT01303341 ↗

“RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.” NCT01158287 ↗

“RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.” NCT00941967 ↗

“sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor” NCT01324076 ↗

“Patients receive oral erlotinib hydrochloride once daily and oral sorafenib tosylate twice daily on days 1-28.” NCT00801385 ↗

“Patients receive oral sorafenib tosylate twice daily on days 1-28 and bevacizumab IV on days 1 and 15.” NCT00867321 ↗

“I. Efficacy of BAY 43-9006 (sorafenib tosylate) by evaluating response rate.” NCT00126659 ↗

“Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.” NCT04344158 ↗

Show 38 more sources